Voydeya approved in the USA for PNH

Marking a second regulatory authorization, Voydeya (danicopan) has now been approved in the USA as add-on therapy for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).

Developed by Alexion Pharmaceuticals, danicopan was picked up by UK pharma major AstraZeneca (LSE: AZN) through its $39 billion acquisition of the rare disease specialist.

Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the around 10%-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.